Adapting therapy with repeated short-infusions to inter individual variability between patients

  • I. D. Rosca
  • J. M. Vergnaud


Because of the wide inter individual variability between patients and their marked differences in drug response, one of the major issues that arises is adapting the therapy in question to the particular patient. In hospital, it is possible to vary the conditions of intravenous (i.v.) drug delivery by means of short infusions repeated at certain intervals. In this study, review of this process has been presented, and a therapeutic method described. It essentially consists of two stages. The first concerns the time of the first infusion, and the course of drug elimination: from two analyses of the drug concentrations in the blood made at two different times, the pharmacokinetic parameters of the patient are determined. Stage 2 consists of repeated short infusions and the therapy is adapted to the particular patient by varying the conditions involved. Thus, either the amount of the dose based on the rate of infusion or the time interval between the repeated infusions are varied. In order to reach a general solution, master curves are built by using dimensionless numbers as co-ordinates, such as time expressed in terms of the half-lifet 0.5 of the drug, and the drug concentration at the peaks defined as a fraction of the first unchanged peak concentration.

Key words

Intravenous administration short infusion inter individual variability adapted therapy pharmacokinetics modelling master curves 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vergnaud J.M. and Rosea I.D. (2005): Assessing bioavailability of drug delivery systems. CRC Press, Taylor & Francis Group: Boca Raton, FL, USA.Google Scholar
  2. 2.
    Smith D.A., Van de Waterbeemd H. and Walker D.K. (2001): Pharmacokinetics and metabolism in drug design. Methods and principles in medicinal chemistry, Wiley-VCH: Weinheim, Germany, vol. 12, ch. 2.Google Scholar
  3. 3.
    Dictionnaire Vidal, Vidal Publ. (2005): 2 rue Béranger, 75140 Paris, cedex 03, France.Google Scholar
  4. 4.
    Campoli-Richards D.M., Monk J.P., Price A., Benfield P., Todd P.A and Ward A. (1988): Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drug evaluation. Drugs, 35, 373–447.CrossRefPubMedGoogle Scholar
  5. 5.
    Breilh D., Saux M.C., Maire P., Vergnaud J.M. and Jelliffe R.W. (2001): Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. Comput. Biol. Med., 31,147–155.CrossRefPubMedGoogle Scholar
  6. 6.
    Wise R. and Donovan, I. (1987): Tissue penetration and metabolism of ciprofloxacin. Am. J. Med., 82 (Suppl. 4 A), 103–107.PubMedGoogle Scholar
  7. 7.
    Fabre D., Bressole F., Gomeni R., Arich C., Lemesle F., Beziau H. and Galtier M. (1991): Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob. Agents Chemother., 35,2521–2525.PubMedGoogle Scholar
  8. 8.
    Smith M.J., White L.O., Bourgee H., Willis J., Hodson M.E. and Batten J.C.(1986): Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob. Agents Chemother., 30, 614–616.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Polymer ChemistryPolytechnic UniversityBucharestRomania
  2. 2.University of Saint-EtienneSaint-EtienneFrance

Personalised recommendations